Phase III trials for the VLA1553 vaccine against chikungunya virus indicated promising results by inducing…
Infection with dengue virus makes mosquitoes more sensitive to warmer temperatures, as does infection with…
Scientists from Imperial College London (UK) and the Wellcome Sanger Institute (Cambridge, UK) have mapped…
Malara parasites showing artemisinin resistance previously seen in South-East Asia have recently emerged in areas of Rwanda in Sub-Saharan Africa. If the mutation causing resistance becomes prevalent across the continent it could have major public health impacts.
The first clinical trial assessing two triple artemisinin-based combination therapies (TACTs) for treating malaria has suggested these are effective and present no safety concerns.
Upon investigating links between the risk of malaria in developing countries and the products demanded by consumers worldwide, researchers have estimated that a significant fraction of the malaria risk in deforestation hotspots is driven by the international trade of products.
Large-scale trials see decrease in dengue infections following release of Wolbachia-infected mosquitos
A team of researchers presented the first large-scale evidence that releasing Wolbachia-infected mosquitoes reduced dengue infections by >70% in high-risk populations.
In this interview we speak to Daniella Lefteri about her research on modulating arbovirus infection by targeting mosquito saliva, and what avenues this could present for new antiviral treatments.
New research has assessed a genetically engineered fungus for the control of malaria mosquitoes in the first semi-field trial, demonstrating that populations were reduced by more than 99%.
A review of Venezuela’s current crisis has given cause for concern, highlighting the increased rate of re-emergence and spread of vector-borne diseases such as malaria, Chagas disease, dengue and Zika virus.